Literature DB >> 11044095

Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

L K Hallak1, D Spillmann, P L Collins, M E Peeples.   

Abstract

Glycosaminoglycans (GAGs) on the surface of cultured cells are important in the first step of efficient respiratory syncytial virus (RSV) infection. We evaluated the importance of sulfation, the major biosynthetic modification of GAGs, using an improved recombinant green fluorescent protein-expressing RSV (rgRSV) to assay infection. Pretreatment of HEp-2 cells with 50 mM sodium chlorate, a selective inhibitor of sulfation, for 48 h prior to inoculation reduced the efficiency of rgRSV infection to 40%. Infection of a CHO mutant cell line deficient in N-sulfation was three times less efficient than infection of the parental CHO cell line, indicating that N-sulfation is important. In contrast, infection of a cell line deficient in 2-O-sulfation was as efficient as infection of the parental cell line, indicating that 2-O-sulfation is not required for RSV infection. Incubating RSV with the purified soluble heparin, the prototype GAG, before inoculation had previously been shown to neutralize its infectivity. Here we tested chemically modified heparin chains that lack their N-, C6-O-, or C2-O-sulfate groups. Only heparin chains lacking the N-sulfate group lost the ability to neutralize infection, confirming that N-sulfation, but not C6-O- or C2-O-sulfation, is important for RSV infection. Analysis of heparin fragments identified the 10-saccharide chain as the minimum size that can neutralize RSV infectivity. Taken together, these results show that, while sulfate modification is important for the ability of GAGs to mediate RSV infection, only certain sulfate groups are required. This specificity indicates that the role of cell surface GAGs in RSV infection is not based on a simple charge interaction between the virus and sulfate groups but instead involves a specific GAG structural configuration that includes N-sulfate and a minimum of 10 saccharide subunits. These elements, in addition to iduronic acid demonstrated previously (L. K. Hallak, P. L. Collins, W. Knudson, and M. E. Peeples, Virology 271:264-275, 2000), partially define cell surface molecules important for RSV infection of cultured cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044095      PMCID: PMC110925          DOI: 10.1128/jvi.74.22.10508-10513.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain.

Authors:  J C Hsiao; C S Chung; W Chang
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

Authors:  L S Wyatt; B Moss; S Rozenblatt
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

Review 3.  More to "heparin" than anticoagulation.

Authors:  U Lindahl; K Lidholt; D Spillmann; L Kjellén
Journal:  Thromb Res       Date:  1994-07-01       Impact factor: 3.944

4.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  The interaction of heparin sulfate and adeno-associated virus 2.

Authors:  J Qiu; A Handa; M Kirby; K E Brown
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

6.  A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry.

Authors:  D Shukla; J Liu; P Blaiklock; N W Shworak; X Bai; J D Esko; G H Cohen; R J Eisenberg; R D Rosenberg; P G Spear
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

7.  Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

Authors:  S S Whitehead; A Bukreyev; M N Teng; C Y Firestone; M St Claire; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

9.  Cellular receptor structures for pseudorabies virus are blocked by antithrombin III.

Authors:  A Voigt; D Sawitzky; H Zeichhardt; K O Habermehl
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402

10.  Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor.

Authors:  W B Klimstra; K D Ryman; R E Johnston
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more
  155 in total

1.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

3.  Residues of the human metapneumovirus fusion (F) protein critical for its strain-related fusion phenotype: implications for the virus replication cycle.

Authors:  Vicente Mas; Sander Herfst; Albert D M E Osterhaus; Ron A M Fouchier; José A Melero
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

4.  Respiratory syncytial virus infection in human bone marrow stromal cells.

Authors:  Fariba Rezaee; Laura F Gibson; Debbie Piktel; Sreekumar Othumpangat; Giovanni Piedimonte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

5.  Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture.

Authors:  Gert Zimmer; Karl-Klaus Conzelmann; Georg Herrler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein.

Authors:  Yuanming Zhang; John C Rassa; Maria Elena deObaldia; Lorraine M Albritton; Susan R Ross
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 9.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

10.  Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge.

Authors:  Stacey M Hartwig; Margaret Ketterer; Michael A Apicella; Steven M Varga
Journal:  Virology       Date:  2016-08-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.